Skip to main content
诺

诺思兰德 — Investor Relations & Filings

Ticker · 920047 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 539 across all filing types
Latest filing 2026-05-07 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920047

About 诺思兰德

Northland Biotech focuses on the research, development, and commercialization of gene therapies and recombinant protein pharmaceuticals. The company’s primary therapeutic areas include cardiovascular diseases, peripheral arterial diseases, and ophthalmology. Its core R&D pipeline features NL003, a hepatocyte growth factor gene therapy targeting critical limb ischemia, and NL005, a recombinant human thymosin beta 4 for treating myocardial ischemia. Beyond its innovative pipeline, the company maintains advanced manufacturing facilities for biologics and ophthalmic preparations, producing a range of specialized eye drops. By leveraging its proprietary technology platforms, Northland Biotech aims to provide effective treatments for chronic and degenerative conditions through advanced molecular medicine.

Recent filings

Filing Released Lang Actions
中泰证券股份有限公司关于北京诺思兰德生物技术股份有限公司2025年度持续督导跟踪报告
Regulatory Filings
2026-05-07 Chinese
第六届董事会第二十八次会议决议公告
Board/Management Information Classification · 1% confidence The document is a board of directors meeting resolution announcement (“第六届董事会第二十八次会议决议公告”), listing all proposals reviewed and approved by the board (annual report, distribution plan, auditor appointment, internal controls, financial statements, budget, board elections, compensation schemes, investments, credit facilities, etc.). It is not a full annual or quarterly report, nor a proxy statement, audit report, or simple regulatory notice. It constitutes Board/Management Information, specifically announcing board resolutions and related management decisions. Therefore, it best fits the Board/Management Information category (MANG).
2026-04-22 Chinese
对外投资设立全资子公司的公告
Regulatory Filings Classification · 1% confidence The document is an announcement by Beijing 诺思兰德生物技术股份有限公司 regarding its decision to make an external investment to establish a wholly-owned subsidiary. It details the investment amount, structure, board approval, and other procedural matters. This is not a fundraising or capital-raising announcement (CAP), nor an M&A bid (TAR), not a board change (MANG), nor a dividend, not a governance report, and not a call transcript. It does not fit any of the specific investment-vehicle or ESG categories. Therefore, it falls under the miscellaneous regulatory announcements category (RNS).
2026-04-22 Chinese
拟续聘2026年度会计师事务所公告
Regulatory Filings Classification · 1% confidence The document is an exchange announcement regarding the proposed re-appointment of the company’s annual audit firm for 2026. It provides details on the audit firm’s credentials, partners, fees and the board’s and audit committee’s approval procedures. It is not the audit report itself, nor an annual/interim financial report, earnings release or management presentation. There is no change in board or senior management, no dividend, capital transaction, or M&A activity. It is a regulatory filing notifying the market of an auditor appointment, which does not fit a more specific category. Thus it falls under the general “Regulatory Filings” category (RNS).
2026-04-22 Chinese
会计师事务所履职情况评估报告
Audit Report / Information Classification · 1% confidence The document is an evaluation report on the performance and independence of the external auditor (中审亚太会计师事务所) for the 2025 annual audit, detailing audit qualifications, procedures, and compliance with relevant regulations. It is not a full annual report nor an announcement or proxy material, but a standalone audit-related assessment. This fits the definition of “Audit Report / Information” (AR).
2026-04-22 Chinese
中泰证券股份有限公司关于北京诺思兰德生物技术股份有限公司2025年度募集资金存放与使用情况的核查报告
Audit Report / Information Classification · 1% confidence The document is a standalone "专项核查报告" issued by the sponsor (中泰证券) on the deposit and use of proceeds raised in 2025, detailing compliance with fund‐use rules. It is not an earnings release, proxy or dividend notice, nor a full annual or interim report. It constitutes an independent assurance/audit‐style report on capital use. Thus it best fits the “Audit Report / Information” category (AR).
2026-04-22 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.